OncoMatch/Clinical Trials/NCT06843967
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Is NCT06843967 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Mirdametinib and Palbociclib for well differentiated liposarcoma.
Treatment: Mirdametinib · Palbociclib — The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CDK4 inhibitor
Exception: Phase II only
Phase II only: Receipt of prior treatment with a selective CDK4 inhibitor
Cannot have received: MEK inhibitor
Exception: Phase II only
Phase II only: Receipt of prior treatment with a selective MEK inhibitor
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9/L; Hemoglobin ≥ 9.0 g/dL; Platelets ≥ 100 x 10^9/L
Kidney function
Creatinine Clearance ≥ 60 mL/min (calculated by Cockcroft-Gault method)
Liver function
Total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN, except patients with Gilbert's disease (≤3x ULN); AST (SGOT) /ALT (SGPT) ≤ 1.5 x institutional ULN
Cardiac function
Systolic blood pressure < 160 mmHg and diastolic blood pressure < 100 mmHg (Grade ≤ 2); LVEF ≥ 50% by MUGA or ECHO; No clinically significant ECG waveform abnormalities assessments at screening
Adequate organ and marrow function as defined below (ULN indicates institutional upper limit of normal): Absolute neutrophil count ≥ 1.5 x 10^9/L; Hemoglobin ≥ 9.0 g/dL; Platelets ≥ 100 x 10^9/L; Total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN, except patients with Gilbert's disease (≤3x ULN); AST (SGOT) /ALT (SGPT) ≤ 1.5 x institutional ULN; Creatinine Clearance ≥ 60 mL/min (calculated by Cockcroft-Gault method); Systolic blood pressure < 160 mmHg and diastolic blood pressure < 100 mmHg (Grade ≤ 2); LVEF ≥ 50% by MUGA or ECHO; No clinically significant ECG waveform abnormalities assessments at screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify